read-more
Read more about Fred Hutch achievements and accolades.
The American Association of Immunologists has selected Fred Hutchinson Cancer Research Center’s Dr. Philip Greenberg, a world expert in cancer immunotherapy, as an AAI 2019 Distinguished Fellow. He is among 52 researchers selected for the inaugural class of fellows.
Immunotherapy, an offshoot of Fred Hutch’s pioneering work in bone marrow transplantation, harnesses the body’s immune system to eliminate cancer cells.
Greenberg, head of the Program in Immunology at Fred Hutch, is also a professor of medicine and immunology at the University of Washington School of Medicine and a member of the Parker Institute for Cancer Immunotherapy. He specializes in a form of immunotherapy called T-cell therapy. His early discoveries about how to target diseases with these immune cells have been foundational for this field.
In the lab and the clinic, Greenberg’s team continues to develop new strategies for genetically reprogramming a patient’s T cells to recognize and kill cancers. They are creating new T-cell therapies for patients with acute myeloid leukemia, ovarian cancer, pancreatic cancer, and other malignancies.
The inaugural class of Distinguished Fellows includes five Nobel laureates (Drs. James Allison of MD Anderson Cancer Center, David Baltimore of the California Institute of Technology, Tasuku Honjo of Kyoto University, Susumu Tonegawa of the Massachusetts Institute of Technology and Rolf Zinkernagel of the University of Zurich).
According to AAI President Dr. JoAnne Flynn, election as a Distinguished Fellow is among the highest honors bestowed by the organization.
The fellows, many of whom Greenberg considers to be longtime friends and colleagues, will be recognized at the AAI annual meeting, Immunology 2019, to be held May 9-13 in San Diego.
